The Early Cancer Institute and CRUK Cambridge Centre Pancreatic Cancer Programme are delighted to invite you to attend this in-person afternoon seminar, 4-6.30pm, followed by networking with food and drinks from 6.30pm.
This seminar brings together experts in the fields of early cancer detection and pancreatic cancer in Cambridge to find out about the current state-of-play and what progress can be made together.
In addition, representatives from two charities (Cancer Research UK and Pancreatic Cancer UK) will be presenting on opportunities within their organisations.
Although this event is free, we would kindly ask that you register to help us organise the venue and catering.
This event is open to members of the CRUK Cambridge Centre or affiliated institutes and is primarily aimed at clinical and non-clinical researchers but other attendees are welcome. If you would like to become a member of the CRUK Cambridge Centre, you can apply for membership here.
Speakers:
We are delighted to welcome Professor Eithne Costello to give a keynote talk about her work on detecting pancreatic cancer earlier. Eithne is Professor of Molecular Oncology at the Institute of Systems, Molecular and Integrative Biology based at The University of Liverpool.
She leads the CRUK-funded UK-Early Detection Initiative for pancreatic cancer, established to detect pancreatic cancer earlier in individuals with new-onset diabetes mellitus. She also chairs the European Study Group for Pancreatic Cancer (ESPAC) translational steering committee.
Other speakers include:
- Dr Anita Balakrishnan, Consultant HPB Surgeon, Cambridge University Hospitals NHS Foundation Trust
- Dr Katja DePaepe, Consultant Radiologist, Cambridge University Hospitals NHS Foundation Trust
- Dr Chris Macdonald, Pancreatic Cancer UK
- Prof Masashi Narita, Cellular Senescence in Cancer and Aging, University of Cambridge
- Dr Alexis Webb, Research Programme Manager for Early Detection, Cancer Research UK
The aim of the seminar is to spark new ideas and collaborations between pancreatic cancer and early detection researchers. We will hear from a number of researchers about the challenges and objectives of pancreatic cancer, and the current work being carried out in Cambridge. There will be a presentation on funding opportunities and a chance to network over drinks.
For more information and to register your place, please visit: www.eventbrite.co.uk/e/cruk-cambridge-centre-early-detection-and-pancreatic-cancer-joint-seminar-tickets-359396483557
About Pancreatic Cancer:
Pancreatic Cancer is a lethal disease with a dismal prognosis, with an overall 5-year survival rate of 7.3%. In the UK, there are around 10,500 new cases every year. Although it is considered a rare cancer by incidence, it is the 5th leading cause of cancer-related mortality, the cause of 9558 deaths per year in the UK in 2017-2019.
Contributing to the poor prognosis associated with pancreatic ductal adenocarcinoma (PDAC) are the lack of early diagnosis, early metastasis and resistance to chemotherapy and radiotherapy. Over half of all patients present with metastatic (Stage IV) disease and even with use of newer chemotherapy regimens, such as FOLFIRINOX and gemcitabine/nab-paclitaxel, the average survival for these patients remains less than a year.
Given the lack of progress in identifying and treating pancreatic cancer, there is a huge need for collaborative cross-discipline discussion and research, to enable the development of novel and integrated approaches to tackling this disease.